Drug Trial Radar · NCT02055638
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
May 2014
Primary completion
May 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups. Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.
Conditions
- Intermittent Explosive Disorder
Interventions
SRX246Drug
capsules
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: from initial dose of intervention until completion of the study up to 8 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Atlanta Center for Medical Research
Atlanta, Georgia
University of Chicago, Department of Psychiatry
Chicago, Illinois
Psychiatric Care and Research Center
O'Fallon, Missouri
SPRI Clinical Trials, LLC
Brooklyn, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Lindner Center of HOPE
Mason, Ohio
Rhode Island Hospital, Department of Psychiatry
Providence, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.